Jump to content

James S. Economou

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 03:38, 19 January 2021 (Alter: doi-broken-date. | You can use this bot yourself. Report bugs here. | Suggested by AManWithNoPlan | Category:CS1 maint: DOI inactive as of December 2020 | via #UCB_Category 67/396). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For the American football player, see James Economou.
James S. Economou
Born (1951-11-07) November 7, 1951 (age 73)
Alma materJohns Hopkins University
Occupation(s)Surgical oncologist, tumor immunologist, UCLA Vice Chancellor For Research

James S. Economou is an |American physician-scientist and university officer. He is currently the Vice Chancellor for Research at the University of California, Los Angeles (UCLA) where he is also a surgical oncologist and tumor immunologist.[1][2] As Research Vice Chancellor at UCLA, he promotes academic entrepreneurship, transdisciplinary research, and support of the humanities, arts, and social sciences. The UCLA research enterprise generates almost one billion dollars in extramural funds annually.[3][4][5]

Early life and education

Economou was born in 1951 in Evanston, Illinois and is the grandson of Greek immigrants.[6] He graduated from New Trier West High School (Northfield, IL), received his BA ('72) and M.D./Ph.D. ('80) from Johns Hopkins University and trained in general surgery at University of California, San Francisco (UCSF). He joined UCLA faculty in 1986, where he has remained for his entire professional career.[7]

James is the son of the late Steven Economou, MD, and Kathryn Dotska Economou.[8]

Career

Economou is the Beaumont Professor of Surgery, Professor of Microbiology, Immunology and Molecular Genetics and Professor of Molecular and Medical Pharmacology at UCLA.[9]

With Arie Belldegrun, he led the first gene therapy trial on the West Coast in the early 1990s and was the founding director of the UCLA Human Gene Medicine Program.[10] He has served as Chief of the UCLA Division of Surgical Oncology since 2000 and was the 65th President of the Society of Surgical Oncology.[11][7] He has also served as a founding member of the Los Angeles Zoo Medical Advisory Board and has operated on a male silverback lowlands gorilla with a large parotid tumor, a Borneo orangutan with a laryngeal sac infection and a single-horned Indian white rhinoceros with cancer.[12][13][14][15][16]

Before becoming the senior research officer of UCLA, he served as deputy director of the UCLA Jonsson Comprehensive Cancer Center.[17] He has chaired two National Cancer Institute Study Sections, has been continuously funded since joining the UCLA faculty, and is on the editorial board of several surgical journals. He received the Stop Cancer Richard Barasch Seed Grant Award (1999),[18] the James Ewing Medal from the Society of Surgical Oncology (2006), and the Flance-Karl Award from the American Surgical Association (2013).[19] January 2014, he became President-elect of the American Surgical Association, the nation's oldest and most prestigious surgical society.[12]

Economou’s research interests in tumor immunology include dendritic cell vaccination, DNA vaccines and adoptive cell therapy using genetically engineered T cells.[20] Economou has served on the Editorial Boards for the American Journal of Surgery, Surgery, the World Journal of Surgery [21] and the Journal of the American College of Surgeons.[22] He has published more than 100 research articles and book chapters.[citation needed] As Vice Chancellor of Research at [UCLA] Economou has promoted a culture of entrepreneurship, diversity, and transdisciplinary scholarship and research.[23][24]

Economou is a co-founder of Kite Pharma,[25][26] a biotechnology company focused on the design and development of immune-based targeted therapies for multiple cancer indications. On June 6, 2014, Kite Pharma announced it had entered into an exclusive, worldwide license with the National Institutes of Health (NIH).[27] Kite Pharma had a successful public offering on June 20, 2014.[28]

Selected publications

  • Jazirehi, A.R.; Kurdistani; Economou, E.S. (2014). "Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway". J. Immunol. 192 (8): 3981–3989. doi:10.4049/jimmunol.1302532. PMC 4136528. PMID 24639349.
  • Butterfield, L.H.; Jilani, S.; Chakraborty, N.G.; Bui, L.A.; Ribas, A.; Dissette, V.; Lau, R.; Gamradt, S.; Glaspy, J.A.; McBride, W.H.; Mukherji, B.; Economou, J.S. (1998). "Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus". Journal of Immunology. 161 (10): 5607–5613. PMID 9820539.
  • Butterfield, L.H.; Meng, W.; Koh, A.; Vollmer, C.M.; Ribas, A. Dissette; Faull, K.; Glaspy, J.A.; McBride, W.H.; Economou, J.S. (2001). "T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein". Journal of Immunology. 166 (8): 5300–5308. doi:10.4049/jimmunol.166.8.5300. PMID 11290817.
  • Ma, C.; Cheung, A.F.; Chodon, T.; Koya, R.C.; Wu, Z.; Ng, C.; Avramis, E.; Cochran, A.J.; Witte, O.N.; Baltimore, D.; Chmielowski, B.; Economou, J.S.; Comin-Anduix, B.; Ribas, A.; Heath, J. (2013). "Multifunctional T cell analyses to study response and progression in adoptive cell transfer immunotherapy". Cancer Discovery. 3 (4): 418–429. doi:10.1158/2159-8290.CD-12-0383. PMC 3716460. PMID 23519018.

2017 retraction. http://mct.aacrjournals.org/content/16/5/977

References

  1. ^ "About the Vice Chancellor for Research". University of California, Los Angeles. Retrieved 20 July 2012.
  2. ^ "Medical School Doctors". David Geffen School of Medicine. Retrieved 8 August 2012.
  3. ^ "The Ecosystem of an Entrepreneurial University". National Collegiate Inventors and Innovators Alliance. 2012-02-06. Retrieved 8 August 2012.
  4. ^ "UCLA continues to lead way for innovation, research in SoCal". UC Health. Retrieved 3 October 2011.
  5. ^ "UCLA ORA PORTAL". University of California, Los Angeles. Retrieved 8 August 2012.
  6. ^ Economou, James S. "Welcoming Remarks to the UCLA Diversity Research Conference".
  7. ^ a b "Society of Surgical Oncology Elects James S. Economou as its President" (PDF). Society of Surgical Oncology. Retrieved 8 August 2012.
  8. ^ "Economou, M.d., Steven G." Chicago Tribune. Retrieved 8 August 2012.
  9. ^ "Faculty Database | David Geffen School of Medicine at UCLA". David Geffen School of Medicine. Retrieved 26 April 2017.
  10. ^ "2013 Milken Insittue Global Conference: Speaker's Biography". Retrieved 3 July 2013.
  11. ^ "A Society in Transition: Presidential Remarks at the 65th Annual SSO Cancer Symposium" (PDF). Society of Surgical Oncology. Retrieved 9 August 2012.
  12. ^ a b Economou, J.S. "A Society in Transition: Presidential Remarks at the 65th Annual SSO Cancer Symposium". [1]. May 2012.
  13. ^ "Zoobiquity Conference". Zoobiquity.com. Retrieved 9 August 2012.
  14. ^ "Randa the Rhino Battles Skin Cancer". KTLA News. Retrieved 16 November 2009.
  15. ^ "New radiation treatment saves cancer-stricken rhinoceros". Atom Watch News. Retrieved 9 August 2012.
  16. ^ UC, Regents. "Physicians Use Skills to Keep Zoo Animals Alive".
  17. ^ "James Economou, Deputy Director, JCCC". Jonsson Comprehensive Cancer Center. Retrieved 8 August 2012.
  18. ^ "STOP CANCER Award". stopcancer.org. Retrieved 9 August 2012.
  19. ^ "American Surgical Association Awards: Flance-Karl Award Recipients". Retrieved 3 July 2013.
  20. ^ "American Association for Cancer Research - James S. Economou Publications". American Association for Cancer Research. Retrieved 8 August 2012.
  21. ^ "World Journal of Surgery:Acknowledgements" (PDF). World Journal of Surgery. 21 (9): 1004. November 1997. doi:10.1007/PL00024610 (inactive 2021-01-19). Retrieved 3 July 2013.{{cite journal}}: CS1 maint: DOI inactive as of January 2021 (link)
  22. ^ "American College of Surgeons Periodicals: Editors". American College of Surgeons. Retrieved 3 July 2013.
  23. ^ "East Bay Express". Retrieved 3 July 2013.
  24. ^ Basken, Paul (2013-08-12). "The Chronicle of Higher Education". The Chronicle of Higher Education. Retrieved 12 August 2013.
  25. ^ "Bloomberg Businessweek Company Overwiew of Kite Pharma". Retrieved 9 August 2012.
  26. ^ "Kite Pharma - Scientific Advisory Board". Kite Pharma. Retrieved 8 August 2012.
  27. ^ Kite Pharma. Press Releases. June 6, 2014.
  28. ^ Calia, Michael. "Kite Pharma Soars Above IPO Price on First Day of Trading. The Wall Street Journal. June 20, 2014.
Retrieved from "https://en.wikipedia.org/w/index.php?title=James_S._Economou&oldid=1001308948"